Home » Newsletters » BioWorld Science

BioWorld Science

June 29, 2022

View Archived Issues

CYSLTR1 blockade as a strategy to prevent breast cancer progression

Researchers identify DAW1 gene variants linked to motile ciliopathy

Design of a novel TAM inhibitor as a potential cancer therapy

Orion Corporation patents new CYP11A1 inhibitors

Wellstat Therapeutics divulges novel uridine derivatives

Eternity Bioscience synthesizes IRAK4 inhibitors

Vilnius University presents new carbonic anhydrase IX ligands

KalVista Pharmaceuticals patents FXIIa inhibitors

[68Ga]NOTA-cc90 demonstrates imaging of LAG-3 expression on tumor-infiltrating lymphocytes

FABP5 inhibitor ART26.12 shows promise for chemotherapy-induced pain

Ono and Fate Therapeutics expand drug discovery collaboration to include CAR-NK cell therapy

FDA clears IND for MALT1 inhibitor SGR-1505 for B-cell lymphomas

BiomX collaborates with Boehringer Ingelheim on biomarkers for IBD-associated pathogenic bacterium

Palleon and Henlius collaborate to codevelop bifunctional sialidase therapeutics

Series B financing at MiroBio funds development of checkpoint agonists to treat autoimmune diseases

miR-135b discriminates tongue cancer from noncancerous tissue

PDX models of radiation-resistant pediatric high-grade glioma show sensitivity to MAPK inhibition

Scorpion selects Exon 20 mutant EGFR inhibitor STX-721 as development candidate

Myelin-forming cells change in multiple brain diseases

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...